A review of the off-label use of selamectin (Stronghold®/Revolution®) in dogs and cats
| Autor: | David J Shanks, Maggie A Fisher |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Veterinary medicine
Cordylobia anthropophaga Review Cat Diseases chemistry.chemical_compound Ivermectin Dogs parasitic diseases Demodicosis medicine Animals Dog Diseases Aelurostrongylus abstrusus lcsh:Veterinary medicine General Veterinary biology Antiparasitic Agents fungi General Medicine Cheyletiella biology.organism_classification medicine.disease Antiparasitic agent Dirofilaria repens medicine.infectious_disease Selamectin chemistry Cats lcsh:SF600-1100 Helminthiasis Animal medicine.drug |
| Zdroj: | Acta Veterinaria Scandinavica, Vol 50, Iss 1, p 46 (2008) Acta Veterinaria Scandinavica |
| ISSN: | 1751-0147 |
| DOI: | 10.1186/1751-0147-50-46 |
| Popis: | Since its introduction approximately seven years ago, selamectin (Stronghold®/Revolution®, Pfizer Inc.) has been used off-label to treat a number of ecto- and endoparasite conditions in dogs and cats. It has been used as a successful prophylactic against Dirofilaria repens and as a treatment for Aelurostrongylus abstrusus in cats. It has also been used to treat notoedric mange, infestation with the nasal mite Pneumonyssoides caninum, Cheyletiella spp. and Neotrombicula autumnalis infestations and larval Cordylobia anthropophaga infection. However, to date attempts to treat generalised canine demodicosis have not been successful. In all cases, treatment was apparently well tolerated by the host. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|